Form 4: Precigen Executive Phil Tennant Acquires 200,000 Stock Options
SEC Form 4
Phil Tennant, Chief Commercial Officer of Precigen, Inc., acquired 200,000 stock options on July 22, 2024, according to a Form 4 filing with the SEC.
Summary
- On July 22, 2024, Phil Tennant, the Chief Commercial Officer of Precigen, Inc. (PGEN), acquired 200,000 options to purchase common stock at an exercise price of $1.61.
- The options vest 25% on July 22, 2025, and the remainder vest in equal monthly installments over the following three years.
- Following the transaction, Mr. Tennant directly owns 200,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could incentivize the executive to improve company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/22/2024 | Date of the stock option grant. |
| 07/22/2025 | 25% of the options vest. |
| 07/22/2034 | Expiration date of the options. |
| 07/24/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.